863 related articles for article (PubMed ID: 19304700)
1. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients.
Boland GW; Blake MA; Holalkere NS; Hahn PF
AJR Am J Roentgenol; 2009 Apr; 192(4):956-62. PubMed ID: 19304700
[TBL] [Abstract][Full Text] [Related]
2. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
3. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
[TBL] [Abstract][Full Text] [Related]
4. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy--initial experience.
Blake MA; Slattery JM; Kalra MK; Halpern EF; Fischman AJ; Mueller PR; Boland GW
Radiology; 2006 Mar; 238(3):970-7. PubMed ID: 16505394
[TBL] [Abstract][Full Text] [Related]
5. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
6. Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm.
Brady MJ; Thomas J; Wong TZ; Franklin KM; Ho LM; Paulson EK
Radiology; 2009 Feb; 250(2):523-30. PubMed ID: 19188319
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET and CT characterization of adrenal lesions in cancer patients.
Jana S; Zhang T; Milstein DM; Isasi CR; Blaufox MD
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):29-35. PubMed ID: 16193311
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT in the evaluation of adrenal masses.
Metser U; Miller E; Lerman H; Lievshitz G; Avital S; Even-Sapir E
J Nucl Med; 2006 Jan; 47(1):32-7. PubMed ID: 16391184
[TBL] [Abstract][Full Text] [Related]
9. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI.
Yun M; Kim W; Alnafisi N; Lacorte L; Jang S; Alavi A
J Nucl Med; 2001 Dec; 42(12):1795-9. PubMed ID: 11752075
[TBL] [Abstract][Full Text] [Related]
11. Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer.
Vikram R; Yeung HD; Macapinlac HA; Iyer RB
AJR Am J Roentgenol; 2008 Nov; 191(5):1545-51. PubMed ID: 18941099
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of unenhanced computed tomography and
Delivanis DA; Bancos I; Atwell TD; Schmit GD; Eiken PW; Natt N; Erickson D; Maraka S; Young WF; Nathan MA
Clin Endocrinol (Oxf); 2018 Jan; 88(1):30-36. PubMed ID: 28815667
[TBL] [Abstract][Full Text] [Related]
13. Solid splenic masses: evaluation with 18F-FDG PET/CT.
Metser U; Miller E; Kessler A; Lerman H; Lievshitz G; Oren R; Even-Sapir E
J Nucl Med; 2005 Jan; 46(1):52-9. PubMed ID: 15632034
[TBL] [Abstract][Full Text] [Related]
14. Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation.
Caoili EM; Korobkin M; Brown RK; Mackie G; Shulkin BL
Acad Radiol; 2007 Apr; 14(4):468-75. PubMed ID: 17368217
[TBL] [Abstract][Full Text] [Related]
15. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT.
Christensen JA; Nathan MA; Mullan BP; Hartman TE; Swensen SJ; Lowe VJ
AJR Am J Roentgenol; 2006 Nov; 187(5):1361-7. PubMed ID: 17056930
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients.
Lu Y; Xie D; Huang W; Gong H; Yu J
Neoplasma; 2010; 57(2):129-34. PubMed ID: 20099976
[TBL] [Abstract][Full Text] [Related]
19. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study.
Guerin C; Pattou F; Brunaud L; Lifante JC; Mirallié E; Haissaguerre M; Huglo D; Olivier P; Houzard C; Ansquer C; Hindié E; Loundou A; Archange C; Tabarin A; Sebag F; Baumstarck K; Taïeb D
J Clin Endocrinol Metab; 2017 Jul; 102(7):2465-2472. PubMed ID: 28431167
[TBL] [Abstract][Full Text] [Related]
20. The value of adding (18)F-FDG PET/CT to adrenal protocol CT for characterizing adrenal metastasis (≥ 10 mm) in oncologic patients.
Park SY; Park BK; Kim CK
AJR Am J Roentgenol; 2014 Feb; 202(2):W153-60. PubMed ID: 24450697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
